{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:21Z","timestamp":1778780121953,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41416-018-0051-8","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T02:23:11Z","timestamp":1522808591000},"page":"1162-1168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A multicentre, open-label, phase-I\/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma"],"prefix":"10.1038","volume":"118","author":[{"given":"D. H.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. T.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fartoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Deptala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Studeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-B.","family":"Loemb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"51_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","volume":"41","author":"D Semela","year":"2004","unstructured":"Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864\u2013880 (2004).","journal-title":"J. Hepatol."},{"key":"51_CR2","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1038\/onc.2010.236","volume":"29","author":"S Whittaker","year":"2010","unstructured":"Whittaker, S., Marais, R. & Zhu, A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989\u20135005 (2010).","journal-title":"Oncogene"},{"key":"51_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292\u2013301 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1440-1746.2012.07096.x","volume":"27","author":"SL Chan","year":"2012","unstructured":"Chan, S. L. & Yeo, W. Targeted therapy of hepatocellular carcinoma: present and future. J. Gastroenterol. Hepatol. 27, 862\u2013872 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"51_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.26679","volume":"59","author":"DS Sandhu","year":"2014","unstructured":"Sandhu, D. S., Baichoo, E. & Roberts, L. R. Fibroblast growth factor signaling in liver carcinogenesis. Hepatology 59, 1166\u20131173 (2014).","journal-title":"Hepatology"},{"key":"51_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"51_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"51_CR8","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S1470-2045(13)70161-X","volume":"14","author":"GK Abou-Alfa","year":"2013","unstructured":"Abou-Alfa, G. K. & Venook, A. P. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol. 14, e283\u2013e288 (2013).","journal-title":"Lancet Oncol."},{"key":"51_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrgastro.2014.10","volume":"11","author":"MA Worns","year":"2014","unstructured":"Worns, M. A. & Galle, P. R. HCC therapies-lessons learned. Nat. Rev. Gastroenterol. Hepatol. 11, 447\u2013452 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"51_CR10","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg, F. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774\u20134782 (2008).","journal-title":"Cancer Res."},{"key":"51_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-2755","volume":"17","author":"K Kudo","year":"2011","unstructured":"Kudo, K. et al. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin. Cancer Res. 17, 1373\u20131381 (2011).","journal-title":"Clin. Cancer Res."},{"key":"51_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/00498254.2010.545452","volume":"41","author":"P Stopfer","year":"2011","unstructured":"Stopfer, P. et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41, 297\u2013311 (2011).","journal-title":"Xenobiotica"},{"key":"51_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698\u2013711 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"51_CR14","doi-asserted-by":"crossref","unstructured":"Yen C.-J., et al. Early data from a phase I study of nintedanib (BIBF 1120) in Asian patients with advanced hepatocellular carcinoma. Ann. Oncol. 23, abstr. 744P (2012).","DOI":"10.1016\/S0923-7534(20)33325-1"},{"key":"51_CR15","unstructured":"Cheng, A.-L et al. Efficacy And Safety of Nintedanib Versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma: A Randomized Phase II Trial. (American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, 2015)."},{"key":"51_CR16","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908\u2013943 (2012).","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"51_CR17","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1200\/JCO.2009.23.1811","volume":"27","author":"SA Cannistra","year":"2009","unstructured":"Cannistra, S. A. Phase II trials in journal of clinical oncology. J. Clin. Oncol. 27, 3073\u20133076 (2009).","journal-title":"J. Clin. Oncol."},{"key":"51_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1078-0432.CCR-09-0694","volume":"16","author":"K Mross","year":"2010","unstructured":"Mross, K. et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res. 16, 311\u2013319 (2010).","journal-title":"Clin. Cancer Res."},{"key":"51_CR19","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-10-0379","volume":"9","author":"I Okamoto","year":"2010","unstructured":"Okamoto, I. et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol. Cancer Ther. 9, 2825\u20132833 (2010).","journal-title":"Mol. Cancer Ther."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0051-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:08Z","timestamp":1684616528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0051-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0051-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H.P reports travel expenses from Boehringer Ingelheim and grants from Bayer, outside the submitted work. A-B.L., J.H., M.S., and D.S. are employees of Boehringer Ingelheim. Y.T.M reports personal fees from Bayer during the conduct of the study. T.M. reports consulting and conference travel expenses. M.P-R reports per patient fees for a phase III trial from Boehringer Ingelheim during the conduct of the study; and grants and personal fees from Bayer Healthcare, Lilly, Arqle-Daiichi, and other from ONXEO, outside the submitted work. P.R., J.G., L.F. and A.D report no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}